October 20
2011
Biodesign Auditorium
727 E. Tyler St. Tempe
AZ 85287
Breast cancer is the second leading cause of deaths among women. In the United States, an estimated 230,480 are diagnosed with breast cancer each year and, of these, 39,520 are expected to die from the disease. This devastating consequence is partly due our inability to detect and provide treatments while the tumor is localized to the breast. As a result, numerous efforts have been made to identify early breast cancer biomarkers. In my talk I will discuss the implications of a number of potential breast cancer biomarkers specifically focusing on the functions of prolactin and its downstream target, Stat5. Unraveling the details of this new mechanism illustrates the complexity of signaling pathways and the formidable challenge of designing chemical intervention.
